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708The Impact of Geographic Proximity to Transplant
Center on Outcomes after Allogeneic Hematopoietic
Stem Cell Transplantation
Karim E. Abou-Nassar,1 Haesook T. Kim,2 Jeff Blossom,3
Vincent T. Ho,4 Robert J. Soiffer,4 Corey S. Cutler,4 Edwin P. Alyea,4 John Koreth,4
Joseph H. Antin,4 Philippe Armand4Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) need access to specialized
care. We hypothesized that access to the transplant center after HSCT may be challenging for patients living
in geographically distant areas, and that this would have an adverse effect on their outcome. We analyzed
1912 adult patients who underwent allogeneic HSCTat theDana-Farber/Brigham andWomen’s Cancer Cen-
ter (DF/BWCC) between 1996 and 2009 andwho resided within 6 hours driving time of the institution. Driv-
ing time from primary residence to DF/BWCC based on zipcode was determined using geographic
information systems. The median driving time (range) to DF/BWCCwas 72 (2-358) minutes. When patients
were stratified by driving time quartile, overall survival (OS) after HSCTwas similar in the first year but worse
after 1 year in patients in the top quartile ($160 minutes driving time). In a landmark analysis of the 909 pa-
tients alive and free of disease at 1 year, 5-year OS was 76% and 65% for patients in the first (#40 minutes)
and fourth ($160 minutes) quartiles, respectively (P 5 .027). This was confirmed in a multivariable analysis.
The difference appeared to be mostly because of an increase in nonrelapse mortality. The number of visits to
the transplant center between day 100 and 365 after HSCT declined significantly with increasing driving time
to the transplant center, which was independently associated with worse survival. Long driving time to the
transplant center is associated with worse OS in patients alive and disease-free 1 year after HSCT,
independently of other patient-, disease-, and HSCT-related variables. This may be in part related to the
lower frequency of post-HSCT visits in patients living farther away.
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6/j.bbmt.2011.08.022Despite major advances in supportive care, complica-
tions still result in significant treatment-related
mortality. Moreover, many of the complications of
HSCT, such as opportunistic infections, and acute
and chronic graft-versus-host disease (aGVHD,
cGVHD), are rarely seen outside of the HSCT setting.
Their detection and management require high vigi-
lance, a low threshold to intervene, and highly special-
ized knowledge [1]. As a result, HSCT is mostly
performed in experienced and accredited transplant
centers [2]. In other clinical settings, it has been shown
that patients residing in rural areas have to travel consid-
erably greater distances than their urban counterparts
to access specialized care [3], resulting in differences
in healthcare access and utilization [4,5]. This may
be particularly relevant in the setting of HSCT where
specialized care is paramount. Consequently, patients
residing in geographically remote areas to the
transplant center could potentially be at higher risk of
adverse outcome after HSCT.
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undergoing HSCT in Nebraska, patients from rural
areas undergoing autologous stem cell transplantation
were found to have an 18% increased relative mortality
rate compared with patients from urban areas [6]. Sim-
ilar studies in the allogeneic setting have failed to dem-
onstrate such an association, although they have been
largely underpowered to detect survival differences.
In the present study, we investigated if geographic
proximity to the transplant center affects overall
survival (OS) in a cohort of adult patients who under-
went allogeneic HSCT at Dana-Farber/Brigham and
Women’s Cancer Center (DF/BWCC).METHODS
Patients and Data Source
We studied all consecutive adult patients who
underwent allogeneic HSCT at DF/BWCC between
January 1, 1996 and June 30, 2009. Zipcode of resi-
dence at the time of transplantation for each patient
included in this study was obtained using the Clinical
Operations and Research Information Systems data-
base at DF/BWCC. Each zipcode data point was
geocoded using the ArcGIS 9.3 StreetMap North
America Postal U.S. address locater (ESRI, Redlands,
CA). The location of DF/BWCC was geocoded into
a separate map layer using the U.S. Streets address
locater. The ArcGIS Network Analyst extension
(ESRI) was used to calculate driving distance and aver-
age driving time along the street network from zipcode
of primary residence to DF/BWCC for each patient.
The ESRI Business Analyst 2009 dataset (ESRI) was
used to extract themedian household income and other
relevant census variables for each zipcode. The number
of clinical encounters with HSCT providers at
DF/BWCC after HSCT was obtained for each patient
through the Clinical Operations and Research Infor-
mation Systems at DF/BWCC. Patients residing
more than 6 hours driving time of the institution were
excluded as they were likely to receive their post-
HSCT care in another transplantation center. All
clinical data was derived from the existingHSCT data-
base atDF/BWCC.This studywas approved by the in-
stitutional review board and conducted in accordance
with the principles of the Declaration of Helsinki.
HSCT
Patients received allogeneic HSCT for numerous
indications and under several treatment and investiga-
tional protocols at DF/BWCCover the 13-year period
covered by this study. Bothmyeloablative and reduced-
intensity conditioning regimens were included.
Patients received bone marrow, peripheral-blood
stem cells, or umbilical cord blood from matched or
mismatched, related, or unrelated donors. AcuteGVHDwas graded according to the consensus scoring
system [7]. Supportive care followed institutional
guidelines or protocol requirements.
Statistical Analysis
The primary objective of this retrospective study
was to investigate if geographic proximity affects OS
in this cohort. Patient baseline characteristics were re-
ported descriptively, and compared using a chi-square
test or Kruskal-Wallis test. OS and disease-free sur-
vival (DFS) were calculated using the Kaplan-Meier
method. OS was defined as the time from stem cell
infusion to death from any cause; those alive or lost
to follow-upwere censored at the date last known alive.
DFS was defined as the time from stem cell infusion to
disease relapse, progression, or death from any cause,
whichever occurred first. Patients who were alive with-
out disease relapse or progression were censored at the
time last seen alive and disease free. The log-rank test
was used for comparisons of Kaplan-Meier curves.
Cumulative incidence curves for nonrelapse death and
progression or relapse with or without death were con-
structed reflecting time to progression and time to
nonrelapse death as competing risks. Time to progres-
sion and time to nonrelapse death were measured from
the date of stem cell infusion. Competing risks analysis
was also used to determine the cumulative incidence of
GVHD, considering death without GVHD as a com-
peting risk. The difference between cumulative inci-
dence curves in the presence of a competing risk was
tested using the Gray method [8]. Potential prognostic
factors for survival, progression-free survival, progres-
sion, and nonrelapse death were examined in the pro-
portional hazards model as well as in the competing
risks regression model [9]. The impact of GVHD on
outcome was examined using the proportional hazards
model with GVHD as a time-dependent variable.
Interaction terms including interaction with time
were examined in the proportional hazards regression
model. Proportional hazards assumption for each
variable of interest was tested. All calculations were
performed using SAS 9.2 (SAS Institute, Cary, NC)
and R 2.10 (The CRAN project).RESULTS
Patients
We studied 2185 consecutive patients who under-
went allogeneicHSCTatDF/BWCCbetween January
1, 1996 and June 30, 2009. A total of 107 patients were
excluded because they had received a previous alloge-
neic HSCT. We were unable to generate appropriate
geocodingdata on26patients, and12patients hadmiss-
ing relapse data. Last, we excluded 128 patients residing
more than 6 hours driving time from DF/BWCC. The
remaining 1912 patients were included in the analysis,
Table 1. Baseline Characteristics
Variable No. (%)*
Number of Patients 1912
Driving time, median (range in minutes) 72 (2-358)
Age (years), median (range) 47 (17-73)
Sex
Male 1090 (57)
Female 822 (43)
Race
Caucasian 1779 (93)
Black/African-American 42 (2)
Asian 28 (1)
Other/unknown 63 (3)
Median household income for zipcode of residence,
median (range in thousands of dollars)
51.7 (16.4-154.4)
Disease
AML 634 (33)
ALL 189 (10)
CML 255 (13)
CLL 121 (6)
MDS 218 (11)
MPD† 32 (2)
Low-grade NHLk 66 (3)
High-grade NHL# 197 (10)
HL 72 (4)
MM 68 (4)
Benign hematologic disease 54 (3)
Other 6 (0)
Stage at SCT
CR1/CP1 609 (32)
CR>1/CP>1 274 (14)
Induction failure 274 (14)
PR/AP 323 (17)
Relapse/BC 217 (11)
Untreated 215 (11)
Treatment on protocol
Yes 893 (47)
No 1019 (53)
ECOG performance status at HSCT‡
0 416 (43)
1 448 (46)
2-3 105 (11)
Donor match
MRD 867 (45)
Non-MRD 1045 (55)
MUD 799 (42)
Mismatched 246 (13)
Mismatched unrelated 217 (11)
Mismatched related 29 (2)
Graft source
PB 1177 (62)
BM 640 (33)
PB + BM 6 (0)
UCB 89 (5)
Conditioning
Myeloablative 695 (36)
Nonmyeloablative/reduced intensity 1217 (64)
GVHD prophylaxis
CnI ± Mtx 842 (44)
CnI + Rapa ± Mtx 756 (40)
CnI + MMF 66 (3)
T-cell depletion 214 (11)
Other 34 (2)
CMV serostatus§
Recipient or donor+ 1134 (61)
Sex matching¶
Female to male 448 (24)
Male to female 414 (22)
Female to female 402 (21)
Male to male 639 (34)
Year of HSCT, median (range) 2004 (1996-2009)
Months of follow-up for survivors, median (range) 41 (4-163)
Figure 1. OS by driving time quartiles to DF/BWCC.
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Table 1. Twenty-one percent of patients were lost to
follow-up (defined as no information within 1 year of
last date of data capture, with interval for data capture
of 6 months), with no significant difference in this
percentage by driving time quartile.
OS Analysis of the Entire Cohort
For the entire cohort, OS did not differ signifi-
cantly between driving time quartiles, with 5-year
OS ranging from 44% to 36% (P 5 .22) (Figure 1).
In a multivariable analysis (including age, sex, ethnic-
ity, median household income, disease, stage at
HSCT, performance status at HSCT, conditioning
intensity, graft source, donor type, GVHD prophy-
laxis, CMV status, year of transplantation, and
whether HSCT was done on protocol), driving time
from primary residence to DF/BWCC was not signif-
icantly associated with OS (hazard ratio [HR] for
mortality for the fourth compared with the first
quartile 5 0.9, P 5 .5). However, this covariate failed
to meet the proportional hazards assumptions; theAML indicates acute myeloid leukemia; ALL, acute lymphoblastic leuke-
mia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic
leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative dis-
order; NHL, non-Hodgkin lymphoma; HL, Hodgkin’s lymphoma; MM,
multiple myeloma; CR, complete remission; CP, chronic phase; PR, par-
tial remission; AP, accelerated phase; BC, blast crisis; MRD, matched re-
lated donor; MUD, matched unrelated donor; PB, peripheral blood; BM,
bone marrow; UCB, umbilical cord blood; CnI, calcineurin inhibitor;
MTX, methotrexate; Rapa: rapamycin.
*Percentages may not add to 100 because of rounding.
†Including mixed MPD/MDS.
‡Data missing on 943 patients.
§Data missing on 41 patients.
¶Donor sex data missing on 9 patients.
kLow-gradeNHL includes: follicular lymphoma, lymphoplasmacytic lym-
phoma, marginal zone lymphoma.
#High-grade NHL includes all histologies not found in low-grade NHL.
Table 2. Baseline Patient Characteristics for Patients Alive and Disease Free at 12 Months (Landmark Analysis) Based on Driving
Time to DF/BWCC
Variable Total Patients, No. (%)* #40 Minutes 41-159 Minutes $160 Minutes P Value†
Number of patients 909 245 440 225
Driving time, median (range in minutes) 73 (3-356)
Number of visits between day 100 and day 365, median (range) 11 (0-38) 14 (0-38) 11 (0-36) 8 (0-25) <.0001
Age (years), median (range) 46 (17-72) 47 (18-72) 45 (17-71) 46 (18-67) .15
Sex
Male 511 (56) 150 (61) 241 (55) 120 (54) .17
Race .0002
Caucasian 844 (93) 215 (88) 414 (94) 215 (96)
Black/African-American 21 (2) 9 (4) 8 (2) 4 (2)
Asian 12 (1) 10 (4) 1 (0) 1 (0)
Other/unknown 32 (4) 11 (4) 17 (4) 4 (2)
Median household income, median (range in thousands of dollars) 52.1 (16.4-154.4) 61.3 (26.8-154.4) 51.7 (16.4-107.9) 42.6 (25.2-140.7) <.0001
Disease 0.16
AML 280 (31) 85 (35) 125 (28) 70 (31)
ALL 83 (9) 19 (8) 43 (10) 21 (9)
CML 158 (17) 36 (15) 83 (19) 39 (17)
CLL 67 (7) 16 (7) 32 (7) 19 (8)
MDS 92 (10) 24 (10) 41 (9) 27 (12)
MPD‡ 12 (1) 3 (1) 5 (1) 4 (2)
Low grade NHL** 40 (4) 9 (4) 23 (5) 8 (4)
High grade NHL†† 79 (9) 34 (14) 34 (8) 11 (5)
HL 33 (4) 6 (2) 18 (4) 9 (4)
MM 23 (3) 1 (0) 16 (4) 6 (3)
Benign hematologic disease 39 (4) 11 (4) 18 (4) 10 (4)
Other 3 (0) 1 (0) 2 (0) 0 (0)
Stage at SCT .74
CR1/CP1 346 (38) 90 (37) 166 (38) 90 (40)
CR>1/CP>1 130 (14) 36 (15) 68 (15) 16 (12)
Induction Failure 109 (12) 33 (13) 53 (12) 23 (10)
PR/AP 143 (16) 36 (15) 75 (17) 32 (14)
Relapse/BC 74 (8) 20 (8) 31 (7) 23 (10)
Untreated 107 (12) 30 (12) 47 (11) 30 (13)
Treatment on protocol .28
Yes 450 (50) 111 (45) 222 (50) 117 (52)
ECOG performance status at SCT¶ .46
0 241 (50) 64 (46) 119 (52) 58 (50)
1 200 (42) 64 (46) 86 (38) 50 (43)
2-3 39 (8) 10 (7) 22 (10) 7 (6)
Donor match 0.45
MRD 428 (47) 109 (44) 206 (47) 113 (50)
Non-MRD 481 (53) 136 (56) 234 (53) 111 (50)
MUD 372 (41) 98 (40) 184 (42) 90 (40)
MM 109 (12) 38 (16) 50 (11) 21 (9)
Mismatched URD 97 (11) 35 (14) 44 (10) 18 (8)
Mismatched relative 12 (1) 3 (1) 6 (1) 3 (1)
Graft source .16
PB 543 (60) 156 (64) 254 (58) 133 (59)
BM 319 (35) 72 (29) 164 (37) 83 (37)
PB + BM 4 (0) 1 (0) 1 (0) 2 (1)
UCB 43 (5) 16 (7) 21 (5) 6 (3)
Conditioning .049
NMA/RIC 296 (33) 95 (39) 131 (30) 70 (31)
GVHD prophylaxis .24
CnI ± Mtx 406 (45) 100 (41) 197 (45) 109 (49)
CnI + Rapa ± Mtx 355 (39) 105 (43) 174 (40) 76 (34)
CnI + MMF 32 (4) 13 (5) 13 (3) 6 (3)
T cell depletion 104 (11) 25 (10) 48 (11) 31 (14)
Other 12 (1) 2 (1) 8 (2) 2 (1)
CMV serostatusk .52
Recipient or donor+ 522 (59) 146 (61) 253 (59) 98 (56)
Sex matching# .042
Mismatched 420 (46) 128 (52) 186 (42) 106 (48)
GVHD cumulative incidence
Acute GVHD 2-4 24% 26% 24% 23% .6
Acute GVHD 3-4 7% 6% 7% 8% .7
Chronic GVHD 52% 57% 51% 48% .062
Year of SCT, median (range) 2004 (1996-2009) 2004 (1996-2009) 2004 (1996-2009) 2004 (1996-2009) .070
Months of follow-up for survivors, median (range) 48 (12-163) 48 (12-150) 49 (12-148) 48 (12-163) .87
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia;
MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma; HL, Hodgkin’s lymphoma; MM, multiple myeloma;
CR, complete remission; CP, chronic phase; PR, partial remission; AP, accelerated phase; BC, blast crisis; MRD, matched related donor; MUD, matched
unrelated donor; PB, peripheral blood; BM, bone marrow; UCB, umbilical cord blood; CnI, calcineurin inhibitor; MTX, methotrexate; Rapa: rapamycin.
*Percentages may not add to 100 because of rounding.
†By Kruskal-Wallis test for continuous variables and chi-square test for discrete variables.
‡Including mixed MPD/MDS.
¶Data missing on 429 patients.
kRecipient or donor status missing on 20 patients.
#Donor sex data missing on 2 patients.
**Low-grade NHL includes: follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma.
††High-grade NHL includes all histologies not found in low-grade NHL.
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Figure 2. OS by driving time to DF/BWCC for patients alive and free
of disease at 12 months: landmark analysis.
712 Biol Blood Marrow Transplant 18:708-715, 2012K. E. Abou-Nassar et al.effect on OS appeared stronger with increasing time
from HSCT (see Figure 1). Indeed, driving time was
significantly associated with OS when entered as
a time-varying covariate in the model (HR of time-
varying term for the fourth quartile compared with
the first quartile 5 1.02, P 5 .0007). This implies
that the impact of driving time on OS becomes more
pronounced further out from HSCT. Based on this
finding, we performed a landmark analysis on all
patients alive and free of disease at 12 months.
Landmark Analysis
A total of 909 patients remained alive and free of
disease at 1 year after HSCT. Baseline characteristics
stratified by driving time from primary residence to
DF/BWCC are shown in Table 2. Patients in the
second and third quartiles had similar OS and thus
were grouped together. Significant differences
between driving time quartiles were found for race,
income, and donor-recipient sex match (Table 2).
After a median follow-up for survivors of 48 months,
the 5-year OS was 76% (95% confidence interval
[CI], 68%-81%) in patients residing within 40 min-
utes, 72% (95% CI, 67%-77%) in those residing be-
tween 41 and 159 minutes, and 65% (95% CI, 57%-
72%) in patients residing 160 minutes or more away
from DF/BWCC (P 5 .027) (Figure 2). Similarly, 5-
year DFS declined with increasing driving time to
DF/BWCC (5-year DFS 67%, 67%, and 58%, respec-
tively, P 5 .038). The 5-year OS of patients alive and
disease free at 1 year but residing .6 hours away
(who were excluded from the above landmark analysis,
as described in the Methods section) was 67% (95%
CI, 50%-79%), similar to the OS of patients living in
the fourth driving time quartile.
A multivariable Cox model for OS among patients
alive and disease free at 12 months was constructed
with the same covariates as above (see Table 3). The
following were significantly associated with OS: age,
disease type, stage at HSCT, donor type, graft source,
conditioning, and driving time from primary residence
to DF/BWCC. The HR for death for patients in the
fourth quartile, compared with the first, was 1.8
(P 5 .004), and the corresponding HR for relapse or
death was 1.5 (P5 .03). Driving time remained signif-
icantly associated with OS in the landmark population
when treated as a continuous variable (HR 5 1.002,
P 5 .018). Notably, income, race, and sex mismatch
(which differed significantly among driving time quar-
tiles) were not significant in this model (Table 3).
Furthermore, in a separate analysis, state of residence
was not an independent prognostic factor if driving
time was included in the model (data not shown). In
an additional landmark analysis of patients alive and
disease free at 100 days, driving time in the fourth
quartile was still significantly associated with increased
mortality compared with the first quartile (HR formortality compared with patients in the first quartile
1.3, P 5 .019).
In competing risks regression models based on our
landmark population of patients alive and disease free at
1 year, there appeared to be a trend for increased
nonrelapse mortality in the fourth quartile (HR 5 1.6,
P 5 .07), but not for relapse (HR 5 1.3, P 5 .2). The
addition of GVHD to the model did not affect the
results of our landmark analysis. A history of severe
(grade 3-4) aGVHDhad an adverse effect onOS (HR5
1.6, P5 .032), while a history of cGVHD by 1 year did
not (HR 5 1.1, P 5 .4); however, the adverse effect of
distance remained unchanged in a model that included
aGVHD and cGVHD (HR for driving time $160
minutes compared with#40 minutes5 1.8, P5 .003).
Post-HSCT Care Utilization
To examine the possible causes of increased mor-
tality in patients residing in geographically distant
areas to the transplantation center, we performed an
exploratory analysis of the impact of the number of
visits at DF/BWCC on outcome. We considered the
number of visits between day 100 and day 365, reason-
ing that starting at day 100 should eliminate the
variability associated with the length and complexity
of the initial transplantation hospitalization, and stop-
ping at day 365 because this was the beginning of the
landmark analysis. The median number of clinical
encounters with HSCT providers at DF/BWCC
between day 100 and 365 after HSCT in patients alive
and free of disease at 1 year was 11 (range: 0-38) (see
Table 2). Patients in the first quartile of driving time
had significantly more clinical encounters (median
14) than patients in the second, third, (median 11),
and the fourth quartiles (median 8) (P\ .0001). We
hypothesized that patients with an uneventful post-
HSCT course would be seen on average every 4 to
Table 3. Multivariable Analyses in Patients Alive and Free of Disease at 12 Months
Variable
OS DFS Relapse NRM
HR P HR P HR P HR P
Age
$50 Ref Ref Ref Ref
<40 0.45 <0.0001 0.57 0.001 0.7 0.2 0.6 .08
40-49 0.65 0.01 0.82 0.2 1.0 0.9 1.5 .10
Sex
Female Ref Ref Ref Ref
Male 1.20 0.2 1.07 0.58 0.9 0.4 1.4 .1
Income quartile
Q1 Ref Ref Ref Ref
Q2 1.32 0.17 1.22 0.26 0.9 0.8 1.6 .08
Q3 1.03 0.89 0.94 0.72 0.8 0.5 1.2 .6
Q4 1.13 0.56 0.97 0.89 0.8 0.3 1.3 .33
Race
Non-Caucasian Ref Ref Ref Ref
Caucasian 0.89 0.69 0.80 0.38 0.7 0.3 0.9 .9
CMV+ (donor or recipient)
Negative Ref Ref Ref Ref
Positive 1.19 0.24 1.08 0.55 0.8 0.3 1.4 .1
Disease*
Low risk Ref Ref Ref Ref
Int risk 2.16 0.003 2.02 0.001 2.2 0.008 1.6 .2
High risk 3.28 <0.0001 2.38 0.0003 3.3 0.0002 1.2 .6
Donor sex
Male Ref Ref Ref Ref
Female 0.94 0.64 0.93 0.54 0.8 0.2 1.1 .6
Stage at SCT†
Low risk Ref Ref Ref Ref
Int risk 1.80 0.002 1.6 0.006 1.9 0.006 1.2 .5
High risk 1.93 0.0003 1.7 0.001 2.2 0.0004 1.2 .6
Donor type
MUD Ref Ref Ref Ref
MRD 0.98 0.05 0.98 0.89 1.8 0.003 0.5 .001
Mismatched 0.84 0.60 0.84 0.50 0.9 0.7 0.8 .6
Graft source
BM Ref Ref Ref Ref
UCB 1.94 0.18 1.94 0.12 3.3 0.039 0.5 .4
PB 1.11 0.66 0.83 0.36 0.5 0.018 1.5 .3
Conditioning
Myeloablative Ref Ref Ref Ref
Reduced intensity 0.76 0.17 0.97 0.86 1.7 0.04 0.5 .023
GVHD prophylaxis
CnI combination Ref Ref Ref Ref
T cell depletion 1.11 0.65 1.00 1.00 0.8 0.6 1.3 .4
Rapa containing 1.21 0.28 1.1 0.57 1.0 0.9 1.2 .4
Protocol
Off protocol HSCT Ref Ref Ref Ref
On protocol HSCT 0.80 0.15 0.87 0.34 0.6 0.028 1.4 .11
Year of HSCT
<2002 Ref Ref Ref Ref
$2002 0.76 0.26 0.86 0.49 0.7 0.14 1.1 .8
Driving time
#40 minutes Ref Ref Ref Ref
41-159 minutes 1.3 0.14 1.2 0.49 0.9 0.6 1.4 .2
$160 minutes 1.8 0.004 1.5 0.03 1.3 0.3 1.7 .076
NRM indicates nonrelapse mortality; CMV, cytomegalovirus; MUD, matched unrelated donor; MRD, matched related donor; BM, bone marrow; UCB,
umbilical cord blood; PB, peripheral blood; Ref, reference group.
*Low-risk disease: benign hematologic disease, low-grade NHL, CLL.
Intermediate-risk disease: MDS, MM, high grade NHL, HL, CML, MPD.
High-risk disease: AML, ALL, other.
†Low-risk stage: CR1, CR2.
Intermediate-risk stage: untreated, PR.
High-risk stage: relapse, CR 3, induction failure.
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between day 100 and day 365. We established this as
our reference group (n5 205). In the landmark popu-
lation, the 5-year OS of patients with 0 to 6 visits(n5 152) was significantly inferior to that of the refer-
ence group, as was the OS of patients with .9 visits
(n 5 552) during this time period (Figure 3). Based
on these findings, the number of visits between day
Figure 3. OS according to number of visits to DF/BWCC between day
100 and 365 postallogeneic HSCT for patients alive and free of disease at
12 months.
714 Biol Blood Marrow Transplant 18:708-715, 2012K. E. Abou-Nassar et al.100 and 365 post-HSCTwas incorporated in the land-
mark multivariable analysis. In this model, patients
with 0 to 6 visits and.9 visits had a significantly higher
mortality compared with patients with 7 to 9 visits
(HR 5 2.2 and 2.30, P 5 .001 and\.0001, respec-
tively). Driving time remained significant (HR in the
fourth compared with the first quartile 5 2.2,
P 5 .0004). The results were similar if the reference
range for an ‘‘appropriate’’ uneventful follow-up was
set as 7 to 11 visits instead of 7 to 9, with 5-year OS
of 68%, 78%, and 68%, for patients with 0 to 6, 7 to
11, and .11 visits, respectively (P 5 .055). There
was no impact of visit history between 1 and 2 years
on OS in a landmark analysis of patients alive and
disease free at 2 years.
The impact of visit number on survival appeared to
be more marked in patients residing farther away, as
there appeared to be no adverse effect of low or high
number of visits for patients residing within 40 min-
utes of the transplantation center, unlike for patients
living more than 40 minutes away (not shown). In an
attempt to estimate the potential number of patients
receiving care in another HSCT center, we looked at
the number of patients in the landmark population
who had 0 visits between day 100 and 365 as these
patients would have received the totality of their
post-HSCT care elsewhere. Among 909 patients,
12 (1%) patients had 0 encounters in this time period.DISCUSSION
This study is thefirst todemonstrate, applyingmod-
ernGIS technology in a largeHSCTcohort, that a high
($160 minutes) driving time to the transplantation
center is associated with significantly worse OS after
allogeneic HSCT. The effect of driving time on OS
becomes apparent after 1 year, independently of otherpatient-, disease-, and HSCT-related variables, and is
more pronounced on nonrelapse mortality than on
relapse. Furthermore, our data suggests that increasing
driving time to the transplantation center is associated
with decreased post-HSCT care utilization at the trans-
plantation center, which may contribute to the adverse
impact of driving time on survival.
Despite an increasing number of studies addressing
disparities in cancer survival based on geographic
proximity to the treatment center [4,10-15], few have
focused on HSCT. In a recent retrospective study
from Nebraska, primary area of residence was evaluated
as an independent risk factor for OS in 1739 patients
undergoing autologous and 267 patients undergoing
allogeneic HSCT to treat selected hematologic
malignancies between 1983 and 2004. Among the
autologous HSCT patients, those from rural areas were
found to have a higher mortality compared with those
from urban areas. However, a comparable difference
was not found among the patients undergoing
allogeneic HSCT [6]. A smaller registry study from
the province of Manitoba, Canada, failed to show
significant survival differences between urban and
rural patients undergoing autologous or allogeneic
transplantation for hematologic malignancies [16].
These important studies may have been underpow-
ered to detect differences in OS based on geographic
proximity. Moreover, actual estimates of driving dis-
tance and time may more accurately reflect ease of
access to care than the ‘‘rural versus urban’’ distinc-
tion and allow for greater analytical flexibility [17].
Our study, being retrospective in nature, is subject
to selection bias. However, the observed differences in
OS by driving time did not appear to be directly attrib-
utable to measurable differences in patient baseline
characteristics. Although patients in the different
quartiles had significantly different ethnic makeup,
median household income, and donor-recipient sex
matching (Table 2), none of these variables were
significant in the multivariable analysis. Furthermore,
relapse rate at 5 years and the occurrence of aGVHD
and cGVHD at 1 year were not statistically different
across driving time quartiles. Last, the development
of aGVHD or cGVHD by 1 year did not appear to
contribute to the observed differences inOS. Although
we cannot exclude possible confounding by unmea-
sured socioeconomic variables, we hypothesize that
the increase in mortality seen in patients living far
away from the transplantation center could be due at
least in part to decreased access to post-HSCT-
specific care, and hence, worse outcome from HSCT
complications such as infections and GVHD that
should ideally be managed by providers with
transplantation-specific expertise.
This conclusion is supported by the fact that the
number of visits to the transplantation center decreased
with increasing driving time, a finding previously
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Moreover, patients seen less frequently than what one
might consider an appropriate routine follow-up fre-
quency (\7visits betweenday100and365)hada signif-
icantly worse OS compared with our reference group
(7-9 visits). The OS was also worse for patients with
more frequent visits (.9), likely reflecting the fact
that those patients were sicker and in greater need of
care. Frequency of visits remained a significant predic-
tor of OS after HSCT (independently of driving time)
in the multivariable analysis. The choice of a cutoff for
an ‘‘optimal’’ number of visits is naturally arbitrary.
However, there appeared to be a similar, although
less pronounced, effect if the ‘‘optimal’’ range was
defined as 7 to 11 visits between day 100 and day 365.
These findings are the first to suggest that enforc-
ing a minimum follow-up schedule could potentially
result in better outcomes in a transplantation center
that serves a geographically varied population. The
absolute number may vary based on surrounding geo-
graphic and sociodemographic factors as well as avail-
able regional healthcare expertise and resources for
each HSCT center. Although this analysis is explor-
atory in nature, as it is subject to significant confound-
ing, additional studies should be undertaken to confirm
this important observation. Furthermore, measures
such as local physician education, establishment of
HSCT-specific outreach clinics, or the development
of a telemedicine infrastructure, could be studied in
an attempt to optimize HSCT outcomes. Ultimately,
if our findings can be reproduced in other institutions
and geographic settings, new knowledge derived
from this area of research could have far-reaching
implications on the delivery of post-HSCT care.ACKNOWLEDGMENTS
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